A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Endometriosis

In brief

The primary objective of this study is to demonstrate the efficacy and safety of linzagolix administered orally once daily for 3 months at a dose of 75 mg alone or of 200 mg in combination with add-back hormone replacement therapy (ABT: estradiol (E2) 1 mg / norethisterone acetate (NETA) 0.5 mg) versus placebo, in the management of moderate to severe endometriosis-associated pain (EAP).

Key facts

Study ID
NCT03986944
Run by
Kissei Pharmaceutical Co., Ltd.
People needed
85
Starts
2019-05-23
Expected to finish
2021-02-16
Last updated by the study team
2025-04-02

Who can join

Age: 18 and older, up to 49. Sex: female. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.